Eli Lilly $LLY moved higher after reports that the company plans nearly $4B of vaccine acquisitions. The planned deals clear the Tier-1 M&A threshold and extend Lilly’s GLP-1 cash flow into infectious-disease assets.
Jardine Matheson agreed to buy 100% of I-MED Radiology Network at an AUD3.4B ($2.4B) enterprise value. The price equals roughly 11.5x projected adjusted EBITDA for the year ending June 2026, with cash and debt funding and 2026 EPS guidance unchanged.
The FDA has launched a first-of-its-kind pilot using cloud-based causal AI to shorten drug and medical device clinical trial timelines by 20–40%. FDA Chief AI Officer Jeremy Walsh says the approach could also accelerate regulatory approval timelines.
Google DeepMind introduced the AI co-clinician, a multimodal AI agent research initiative to support healthcare workers. In blind evaluations, the system achieved zero critical errors in 97 of 98 primary care queries and matched physician-level performance on medication knowledge benchmarks.
A Harvard Medical School trial found OpenAI's o1 reasoning model correctly diagnosed 67% of ER patients, beating human physicians at 50-55%. With more clinical data, o1 reached 82% accuracy and dominated long-term treatment planning at 89% versus doctors' 34%.
A peer-reviewed study published in Science tested OpenAI's o1 on 76 real ER triage cases and found it achieved exact or near-exact diagnoses 67% of the time, versus 55% and 50% for two attending physicians who received identical patient data.
A new study published in Science found that a state-of-the-art LLM matched or exceeded human emergency physicians in diagnostic choices, emergency triage, and next-step management decisions using real ER data and hundreds of physician comparisons. Researchers say the results call for collaborative care models, not AI replacement of doctors.
$LLY rose more than 10% after Eli Lilly posted Q1 revenue of $19.8 billion, adjusted EPS of $8.55, and lifted its 2026 sales outlook by $2 billion.
The important medical AI story here is not replacement but reliability. Google DeepMind says its AI co-clinician produced zero critical errors in 97 of 98 realistic primary-care queries, while physicians still beat it overall in multimodal telemedicine simulations.
GE HealthCare $GEHC fell 9% after cutting 2026 adjusted EPS guidance to $4.80-$5.00 from $4.95-$5.15. Revenue still rose 7.4% to $5.13 billion, but margins were hit by a supplier issue and higher memory-chip, oil, and freight costs.
OpenAI is moving from generic chat to a healthcare-specific workspace, and the timing is clear: 72% of physicians now report AI use in clinical practice. The new product is free to verified U.S. physicians, NPs, PAs, and pharmacists, and OpenAI says doctors rated 99.6% of tested responses safe and accurate across 6,924 conversations.
Why it matters: OpenAI is targeting a regulated workflow where accuracy claims carry direct clinical consequences. The linked rollout cites 6,924 physician-reviewed conversations and a 99.6% safe/accurate rating in internal review.